RESEARCH GRANTS & CONTRACTS

Dr. George A. Vilos, B.Sc, MD, FRCSC, FACOG, FSOGC
Professor of Obstetrics and Gynecology
The University of Western Ontario
London, Ontario, Canada.
Infertility Research Chair Professor        
King Saud University, Riyadh, Saudi Arabia

1. "Third-party blinded placebo-controlled evaluation of the safety and efficacy of sterile Tolmetin Sodium in adhesion reduction:  Multinational Study".  Sponsored by Johnson and Johnson Company, U.S.A. (Cancelled prior to completion), 1990; Johnson and Johnson Company, USA: participant.
   
   
2. "A Canadian multicentre prospective double-blind randomized study of the utilization of Zoladex vs Placebo (Sham injection) before surgery in infertile women with stage III or IV endometriosis precluding outpatient laparoscopic surgery".  Sponsored by ICI Pharma Canada Inc. (Cancelled prior to completion), 1992; ICI Pharma Canada Inc.: participant. 
   
   
3. ENDOCAN
   "The Relations Between Minimal and Mild Endometriosis and Fecundity:  A Canadian Prospective Multicentre Study".  Sponsored by an MRC Grant (Completed, submitted to Am J Epidemiol), 1994-95; MRC Collaborative Grant: participant. 
   
   
4. ENDOCAN
   "Surgical Laparoscopy in Infertile Women with Minimal or Mild Endometriosis:  A Canadian Multicentre Randomized Controlled Trial".  Sponsored by MRC Grant (Completed, submitted to NEJM), 1994-95; MRC Collaborative Grant: participant.
   
   
5. Feasibility Study of the balloon endometrial ablation system for the treatment of excessive uterine bleeding (Menorrhagia).  A pilot study:  Sponsored by ORIGIN MEDSYSTEMS.  Completed December 31, 1994 (Published J Am Assoc Gynecol Laparoscopists, 1995), 1994-95; Gynecare Inc., USA: Principal investigator.
   
   
6. Comparative study of balloon endometrial ablation system and electrosurgical endometrial ablation for the treatment of excessive uterine bleeding (Menorrhagia).  Sponsored by ORIGIN MEDSYSTEMS.  A multinational study (Published J Am Assoc Gynecol Laparoscopists, 1997), 1995; Gynecare Inc., USA: Principal investigator.
   
   
7. Adjunct Zoladex for thinning of the Endometrium Comparison Study (AZTEC).  Sponsored by ZENECA PHARMA.  A multinational study (Completed, Published Fertility Sterility, 1997), 1994-96; Zeneca Pharma, Principal Co-investigator.
   
   
8. Protocol Scuba - 19003 - A pilot study to evaluate the safety efficacy of the SCUBA (Versapoint) electrosurgical system.  Sponsored by Gynecare, Inc (1996), 1996; Gynecare Inc., USA:  Principal investigator.
   
   
9. 393IL/0025/027.  A multicentre controlled study of Zoladex 10.8 mg 3-month depot plus iron versus sham plus iron for the pre-operative management of premenopausal women with iron deficiency anemia due to uterine fibroids.  Sponsored by ZENECA Pharma Inc (1996-97), Zeneca Pharma Inc., Participant.
   
   
10. 9238IL/0019.  A randomized placebo-controlled dose-ranging trial compraing ICI 182,780 with Zoladex in patients with uterine fibroids awaiting hysterectomy.  Sponsored by ZENECA  Pharma Inc, 1997, Zeneca Pharma Inc., Participant.
    
    
11. Effects of low dose danazol on menorrhagia.  Sponsored by Sanofi-Winthrop 1996;  Principal investigator.
12.  #98-88018-A-LA: Uterine Balloon Therapy (UBT-2) Endometrial Ablation Study. Sponsored by Gynecare Inc., 1998, Principal Investigator.
    
    
13. Surgical Treatment Outcomes Project for Dysfunctional Uterine Bleeding (STOP-DUB). Multicentre Prospective Randomized Trial, Sponsored by gency for Health Care Policy and Research of the Department of Health And Human Services; US Federal Government, 1998.
    
    
14. Uterine Artery Embolization for Symptomatic Fibroids. Pilot Study by Interventional Radiology Collaborative Group 1998, Participant.
    
    
15. Adjunct Zoladex Therapy and Uterine Artery Embolization for the Treatment of Symptomatic Fibroids: A Pilot Study. Principal Investigator 1999-2000.
    
    
16. CDN/99/MIR/01 (Mirena vs Minestrin) 2000-2001. Sponsored by Berlex Canada Inc, Participant.
    
    
17. CDN/99/MIR/02 (Mirena vs Danazol) 2000-2001. Sponsored by Berlex Canada Inc, Participant.
    
    
18. Laser Heating the Endometrium vs Rollerball Endometrial Ablation for the Treatment of Excessive Uterine Bleeding. 2000-2004. Sponsored by ESC Medical Systems Ltd, Participant.
    
    
19. PNU8839. Phase III Study of Depot Medroxyprogesterone Acetate Subcutaneous Injections (CDMPA-SC) in Women with Endometriosis in the United States and Canada. Sponsored by Pharmacia and Upjohn, 2001-2002, Participant.
    
    
20. Protocol No. M01-394. A Phase III, 12-Month Randomized Double-Blind Study to Evaluate the Efficacy and Safety of Two Doses of J867 Isoprisnil) Versus Placebo in Subject. Sponsored by TAP Pharmaceutical Product Inc., 2002-2004, Participant.
    
    
21. MDMI Thermablate Ednometrial/Ablation for Menorrhagia (TEAM) Trial, 2003, Principal Investigator.
    
    
22. ADH-02-2.1. A Controlled Randomized Study to Assess the Safety and Effectiveness of Adhibit Adhesion Prevention Gel in Gynecologic Surgery. Cohesion Technologies. July 2003-2004, Principal Investigator.
    
    
23. VCS-022. A Phase I Study to Evaluate the Feasibility and Safety of Intraoperative Temporary Uterine Artery Occlusion Performed with the Vascular Control Systems Transvaginal Doppler Clamp in Women Undergoing Myomectomy (HSREB No. 9847, 2003-2004), Principal Investigator.
    
    
24. VCS-026. A Phase I Pilot Study to Evaluate the Feasibility and Safety of Temporary Bilateral Uterine Artery Occlusion Performed with the Vascular Control Systems Transvaginal Doppler Clamp for the Treatment of Symptomatic Uterine Fibroids 2004. Sponsored by Vascular Control Systems, Inc., Principal Investigator.
    
    
25. HSREB No. 09014E, 2003 - Endometriosis and Bipolar Disorder: Exploring the Relationship, Participant.
    
    
26. HSREB No. 09735E, 2003 – Towards Single Embryo Transfer in the Human (CIHR Sponsored Participant).
    
    
27. The addition of 17b estradiol to a mood stabilizer in the treatment of major depression with post-partum onsent in patients with bipolar I and bipolar II disorder, Participant.
    
    
28. VSC-030. A Phase 1 Pilot Study to Evaluate the Feasibility and Safety of Temporary Bilateral Uterine Artery Occlusion Performed for Nine Hours with the Vascular Control Systems Transvaginal Uterine Fibroids
    
    ^ Back to top
    
    

    ---

    
    SPONSORED BY VASCULAR CONTROL SYSTEMS, PRINCIPAL INVESTIGATOR
    
    
29. VCS-027. A Phase I Study to Evaluate the Feasibility and Safety of Temporary Bilateal Uterine Artery Occlusion Performed with the Vascular Control Transvaginal Doppler Clamp for the Treatment of Dysfunctional Uterine Bleeding (Sponsored by Vasulcar Control Systems), Principal Investigator.
    
    
30. HSREB NO. 10808, 2004. Validation and Application of the Active Electrode Monitoring (AEM) System to Resectoscopic Electrosurgery (Not Sponsored), Prinicipal Investigator.
    
    
31. HSREB NO. 10943,2004-2005. “Selene- Endometrial Gel Ablation Kit (Sponsored by Mentor Corporation), Principal Investigator (cancelled).
    
    
32. HSREB No. 11208, 2005. A Double-Blind Randomized Placebo-Controlled Dose-Ranging Study of the Effects of ERB-041 in the Reduction of Symptoms Associated with Endometriosis in Reproductive-Age Women (sponsored by Wyeth), Participant.
    
    
33. HSREB No. 11299. Sutureless Hysterectomy: Two Pilot Randomized Studies to Evaluate the Use of a Bipolar Clamp (BiClamp) a Vessel Sealer During Vaginal and Abdominal Hysterectomy (Not Sponsored), Principal Investigator.
    
    
34. HSREB No. 11300. A Pilot Randomized Study to Evaluate the Use of Foley Intrauterine Catheter to Prevent Recurrence of Intrauterine Septum Following Hysteroscopic Septum Division (Not Sponsored), Principal Investigator.
    
    
35. HSREB No. 11829. Protocol No. 3068A1-301-CA. Fracture Incidence Reduction and Safety of TSE 424 (bazedoxifene acetate) compared to placebo and raloxifene in osteoportic postmenopausal women. Participant: Sponsored by Wyeth.
    
    
36. HSREB No. A Double-Blinded, Randomized, Placebo-Controlled Study to Evaluate the Safety and Efficacy of 75 mg and 150 mg Doses of ERB-041 on the Reduction of Symptoms Associated with Endometrosis during Treatment and Post-Treatment in Reproductive-Aged Women (Sponsored by Wyeth), Participant.
    
    
37. HSREB No. 13174. A Pivotal Study of Doppler Guided Uterine Artery Occlusion as Treatment for the Reduction of Fibroid Associated Bleeding. July 2007-April 2011 (Sponsored by Ethicon Inc.).
    
    
38. HSREB No. 13295. A Pilot Study to Compare Post Treatment Pains and Clinical Outcomes of Women with Symptomatic Uterine Fibroids Treated with Transcatheter Gelfoam Pledgets and Embospheres Versus Gelfoam Pledgets Alone (Not Sponsored).
    
    
39. HSREB No. 13417. Randomized Comparison of Rollerball Endometrial Ablation Using Four Different Power Settings (60W, 80W, 100W, 120W): A Pilot Study (Not Sponsored).
    
    
40. REB No. 13418. Randomized Comparison of Cutting Versus Coagulating Waveforms for Hysteroscopy Endometrial Ablation to Treat Menorrhagia Using the Rollerball: A Pilot Study (Not Sponsored).
    
    
41. HSREB No. 13419. A Pilot Study to Compare Clinical Outcomes of Women with Symptomatic Uterine Fibroids Treated with Levonorgestrel IUD vs. Transcatheter UAO using Gelfoam Pledgets (Not Sponsored). RESEARCH
    
    
42. HSREB No. 13740. Mutli-center, open-label, randomized study to assess the safety and contraceptive efficacy of two doses of the ultra low dose levonorgestrel contraceptive intra uterine system (LCS) for maximum 3 years in women 18 to 35 years of age (Sponsored by Bayer).
    
    
43. HSREB No 13849 E. Clinical Outcomes of Women with Abnormal Uterine Bleeding (AUB) Treated By Endometrial Albation and Other Medical Therapies (Not Sponsored). Principal Investigator.

^ Back to top